These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 30157388)

  • 1. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
    Fox RJ; Coffey CS; Conwit R; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Naismith RT; Ashokkumar A; Barnes J; Ecklund D; Klingner E; Koepp M; Long JD; Natarajan S; Thornell B; Yankey J; Bermel RA; Debbins JP; Huang X; Jagodnik P; Lowe MJ; Nakamura K; Narayanan S; Sakaie KE; Thoomukuntla B; Zhou X; Krieger S; Alvarez E; Apperson M; Bashir K; Cohen BA; Coyle PK; Delgado S; Dewitt LD; Flores A; Giesser BS; Goldman MD; Jubelt B; Lava N; Lynch SG; Moses H; Ontaneda D; Perumal JS; Racke M; Repovic P; Riley CS; Severson C; Shinnar S; Suski V; Weinstock-Guttman B; Yadav V; Zabeti A;
    N Engl J Med; 2018 Aug; 379(9):846-855. PubMed ID: 30157388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Coffey CS; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Conwit R; Naismith R; Ashokkumar A; Bermel R; Ecklund D; Koepp M; Long J; Natarajan S; Ramachandran S; Skaramagas T; Thornell B; Yankey J; Agius M; Bashir K; Cohen B; Coyle P; Delgado S; Dewitt D; Flores A; Giesser B; Goldman M; Jubelt B; Lava N; Lynch S; Miravalle A; Moses H; Ontaneda D; Perumal J; Racke M; Repovic P; Riley C; Severson C; Shinnar S; Suski V; Weinstock-Gutman B; Yadav V; Zabeti A
    Contemp Clin Trials; 2016 Sep; 50():166-77. PubMed ID: 27521810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post Hoc Analyses of the SPRINT-MS Trial.
    Ehrhardt H; Lambe J; Moussa H; Vasileiou ES; Kalaitzidis G; Murphy OC; Filippatou AG; Pellegrini N; Douglas M; Davis S; Nagy N; Quiroga A; Hu C; Zambriczki Lee A; Duval A; Fitzgerald KC; Prince JL; Calabresi PA; Sotirchos ES; Bermel R; Saidha S
    Neurology; 2023 Sep; 101(10):e1014-e1024. PubMed ID: 37460235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype.
    Goodman AD; Fedler JK; Yankey J; Klingner EA; Ecklund DJ; Goebel CV; Bermel RA; Chase M; Coffey CS; Klawiter EC; Naismith RT; Fox RJ;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):111-118. PubMed ID: 33460301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
    Bermel RA; Fedler JK; Kaiser P; Novalis C; Schneebaum J; Klingner EA; Williams D; Yankey JW; Ecklund DJ; Chase M; Naismith RT; Klawiter EC; Goodman AD; Coffey CS; Fox RJ
    Mult Scler; 2021 Aug; 27(9):1384-1390. PubMed ID: 33054533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
    Nakamura K; Zheng Y; Mahajan KR; Cohen JA; Fox RJ; Ontaneda D
    Mult Scler; 2023 Sep; 29(10):1257-1265. PubMed ID: 37537928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
    Ladakis DC; Reyes-Mantilla MI; Gadani SP; Mace JW; Dominguez-Penuela SC; Appiah MJ; Smith MD; Bhargava P; Fox RJ; Saidha S; Calabresi PA
    Mult Scler; 2024 Jan; 30(1):35-43. PubMed ID: 37982154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
    Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.
    Naismith RT; Bermel RA; Coffey CS; Goodman AD; Fedler J; Kearney M; Klawiter EC; Nakamura K; Narayanan S; Goebel C; Yankey J; Klingner E; Fox RJ;
    Neurology; 2021 Jan; 96(4):e491-e500. PubMed ID: 33268562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
    Nakamura K; Thoomukuntla B; Bena J; Cohen JA; Fox RJ; Ontaneda D
    Mult Scler; 2024 Mar; 30(3):369-380. PubMed ID: 38286755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
    Chataway J; Schuerer N; Alsanousi A; Chan D; MacManus D; Hunter K; Anderson V; Bangham CR; Clegg S; Nielsen C; Fox NC; Wilkie D; Nicholas JM; Calder VL; Greenwood J; Frost C; Nicholas R
    Lancet; 2014 Jun; 383(9936):2213-21. PubMed ID: 24655729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
    Nicholson S; Russo AW; Brewer K; Bien H; Tobyne SM; Eloyan A; Klawiter EC
    Mult Scler; 2023 Dec; 29(14):1819-1830. PubMed ID: 37947294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibudilast for the treatment of multiple sclerosis.
    Goodman AD; Gyang T; Smith AD
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1231-7. PubMed ID: 27501293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial.
    Ciampi E; Uribe-San-Martin R; Cárcamo C; Cruz JP; Reyes A; Reyes D; Pinto C; Vásquez M; Burgos RA; Hancke J
    BMC Neurol; 2020 May; 20(1):173. PubMed ID: 32380977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
    Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
    Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
    Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety.
    Johnson JL; Kwok YH; Sumracki NM; Swift JE; Hutchinson MR; Johnson K; Williams DB; Tuke J; Rolan PE
    Headache; 2015 Oct; 55(9):1192-208. PubMed ID: 26367865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
    Arnold DL; Piani-Meier D; Bar-Or A; Benedict RH; Cree BA; Giovannoni G; Gold R; Vermersch P; Arnould S; Dahlke F; Hach T; Ritter S; Karlsson G; Kappos L; Fox RJ;
    Mult Scler; 2022 Sep; 28(10):1526-1540. PubMed ID: 35261318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.